Cardiovascular devices are used in treating diseases related to the heart and the circulatory system. Transcatheter Aortic Valve Replacement (TAVR), also known as, Transcatheter Aortic Valve Implantation (TAVI), is a minimally invasive procedure used to treat severe aortic valve stenosis by implanting a Transcatheter Heart Valve in a patient’s diseased aortic valve. GlobalData uses proprietary data and analytics to provide a comprehensive report on the transcatheter aortic valve replacement devices market, including market shares of different players within Italy. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the transcatheter aortic valve replacement market in Italy was Edwards Lifesciences followed by Medtronic, Boston Scientific and Abbott Laboratories.
The procedure is largely performed transfemorally (through the groin) but can also be performed via alternative pathways including the transapical, transaortic, transcarotid, transsubclavian and transcaval approaches.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the transcatheter aortic valve replacement devices market within Italy was expected to be over $200m in 2022.
For the latest complete market share analysis of transcatheter aortic valve replacement device market in Italy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.